A citation-based method for searching scientific literature


List of co-cited articles
979 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity




Sustained-release oral fampridine in multiple sclerosis: a randomised, double-blind, controlled trial.
Andrew D Goodman, Theodore R Brown, Lauren B Krupp, Randall T Schapiro, Steven R Schwid, Ron Cohen, Lawrence N Marinucci, Andrew R Blight. Lancet 2009
364
28

4-Aminopyridine improves clinical signs in multiple sclerosis.
D Stefoski, F A Davis, M Faut, C L Schauf. Ann Neurol 1987
143
27

The effects of 4-aminopyridine in multiple sclerosis patients: results of a randomized, placebo-controlled, double-blind, concentration-controlled, crossover trial.
C T Bever, D Young, P A Anderson, A Krumholz, K Conway, J Leslie, N Eddington, K I Plaisance, H S Panitch, S Dhib-Jalbut. Neurology 1994
142
26

Fampridine-SR in multiple sclerosis: a randomized, double-blind, placebo-controlled, dose-ranging study.
A D Goodman, J A Cohen, A Cross, T Vollmer, M Rizzo, R Cohen, L Marinucci, A R Blight. Mult Scler 2007
111
26


The effect of 4-aminopyridine on clinical signs in multiple sclerosis: a randomized, placebo-controlled, double-blind, cross-over study.
H A van Diemen, C H Polman, T M van Dongen, A C van Loenen, J J Nauta, M J Taphoorn, H K van Walbeek, J C Koetsier. Ann Neurol 1992
129
21


Dose comparison trial of sustained-release fampridine in multiple sclerosis.
A D Goodman, T R Brown, J A Cohen, L B Krupp, R Schapiro, S R Schwid, R Cohen, L N Marinucci, A R Blight. Neurology 2008
128
21

A phase 3 trial of extended release oral dalfampridine in multiple sclerosis.
Andrew D Goodman, Theodore R Brown, Keith R Edwards, Lauren B Krupp, Randall T Schapiro, Ron Cohen, Lawrence N Marinucci, Andrew R Blight. Ann Neurol 2010
236
21


Quantitative assessment of sustained-release 4-aminopyridine for symptomatic treatment of multiple sclerosis.
S R Schwid, M D Petrie, M P McDermott, D S Tierney, D H Mason, A D Goodman. Neurology 1997
144
20

Effects of 4-aminopyridine in patients with multiple sclerosis.
R E Jones, J R Heron, D H Foster, R S Snelgar, R J Mason. J Neurol Sci 1983
121
20

4-Aminopyridine in multiple sclerosis: prolonged administration.
D Stefoski, F A Davis, W E Fitzsimmons, S S Luskin, J Rush, G W Parkhurst. Neurology 1991
87
21


4-aminopyridine in the treatment of patients with multiple sclerosis. Long-term efficacy and safety.
C H Polman, F W Bertelsmann, A C van Loenen, J C Koetsier. Arch Neurol 1994
106
18




Heteromultimeric K+ channels in terminal and juxtaparanodal regions of neurons.
H Wang, D D Kunkel, T M Martin, P A Schwartzkroin, B L Tempel. Nature 1993
526
14

4-Aminopyridine in patients with multiple sclerosis: dosage and serum level related to efficacy and safety.
H A Van Diemen, C H Polman, J C Koetsier, A C Van Loenen, J J Nauta, F W Bertelsmann. Clin Neuropharmacol 1993
72
19

Potassium channel distribution, clustering, and function in remyelinating rat axons.
M N Rasband, J S Trimmer, T L Schwarz, S R Levinson, M H Ellisman, M Schachner, P Shrager. J Neurosci 1998
204
13




4-Aminopyridine induces functional improvement in multiple sclerosis patients: a neurophysiological study.
H A van Diemen, C H Polman, M M van Dongen, J J Nauta, R L Strijers, A C van Loenen, F W Bertelsmann, J C Koetsier. J Neurol Sci 1993
48
22

Molecular dissection of the myelinated axon.
S G Waxman, J M Ritchie. Ann Neurol 1993
244
10

Fatigue in progressive multiple sclerosis: results of a randomized, double-blind, placebo-controlled, crossover trial of oral 4-aminopyridine.
P M Rossini, P Pasqualetti, C Pozzilli, M G Grasso, E Millefiorini, A Graceffa, G A Carlesimo, G Zibellini, C Caltagirone. Mult Scler 2001
92
10


Pharmacokinetics of an immediate-release oral formulation of Fampridine (4-aminopyridine) in normal subjects and patients with spinal cord injury.
K C Hayes, M A Katz, J G Devane, J T C Hsieh, D L Wolfe, P J Potter, A R Blight. J Clin Pharmacol 2003
57
17



Contactin orchestrates assembly of the septate-like junctions at the paranode in myelinated peripheral nerve.
M E Boyle, E O Berglund, K K Murai, L Weber, E Peles, B Ranscht. Neuron 2001
395
9


K+ channel distribution and clustering in developing and hypomyelinated axons of the optic nerve.
M N Rasband, J S Trimmer, E Peles, S R Levinson, P Shrager. J Neurocytol 1999
86
10


Randomized double-blind crossover trial of fampridine-SR (sustained release 4-aminopyridine) in patients with incomplete spinal cord injury.
P J Potter, K C Hayes, J L Segal, J T Hsieh, S R Brunnemann, G A Delaney, D S Tierney, D Mason. J Neurotrauma 1998
69
13

4-Aminopyridine kinetics.
D R Uges, Y J Sohn, B Greijdanus, A H Scaf, S Agoston. Clin Pharmacol Ther 1982
57
15


Characterization of 4-aminopyridine in overdose.
C M Stork, R S Hoffman. J Toxicol Clin Toxicol 1994
46
19

The effects of 4-aminopyridine on cognitive function in patients with multiple sclerosis: a pilot study.
R C Smits, H H Emmen, F W Bertelsmann, B M Kulig, A C van Loenen, C H Polman. Neurology 1994
69
13

Action potentials and membrane currents in the human node of Ranvier.
J R Schwarz, G Reid, H Bostock. Pflugers Arch 1995
182
9

Measuring the impact of MS on walking ability: the 12-Item MS Walking Scale (MSWS-12).
J C Hobart, A Riazi, D L Lamping, R Fitzpatrick, A J Thompson. Neurology 2003
526
9

Multiple measures of axonal excitability: a new approach in clinical testing.
M C Kiernan, D Burke, K V Andersen, H Bostock. Muscle Nerve 2000
340
8

Threshold tracking techniques in the study of human peripheral nerve.
H Bostock, K Cikurel, D Burke. Muscle Nerve 1998
408
8



Development of 4-AP and TEA sensitivities in mammalian myelinated nerve fibers.
D L Eng, T R Gordon, J D Kocsis, S G Waxman. J Neurophysiol 1988
81
9



Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.